Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study
Version of Record online: 1 AUG 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 8, pages 1188–1194, August 2011
How to Cite
de Hollanda, A., Beucher, A., Henrion, D., Ghali, A., Lavigne, C., Lévesque, H., Hamidou, M., Subra, J. F., Ifrah, N. and Belizna, C. (2011), Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study. Arthritis Care Res, 63: 1188–1194. doi: 10.1002/acr.20504
- Issue online: 1 AUG 2011
- Version of Record online: 1 AUG 2011
- Accepted manuscript online: 16 MAY 2011 11:44AM EST
- Manuscript Accepted: 29 APR 2011
- Manuscript Received: 25 APR 2010
The presence of systemic and/or immune manifestations in myelodysplasia has been currently reported. The influence of these manifestations on the natural outcome of myelodysplastic syndrome has to be considered. We present a multicenter retrospective study (2002–2009) of patients with myelodysplastic syndrome disclosing systemic and/or immune manifestations.
Forty-six patients with myelodysplasia presenting with systemic and/or immune manifestations were compared in terms of survival with 189 patients with myelodysplasia lacking these features.
The clinical picture in these cases consisted of fever (13%), arthralgia or arthritis (13%), and cutaneous manifestations (67%). Four cases of systemic vasculitis have been reported in our series, and they have a worse prognosis. Immune anomalies were recorded in 29% of the cases, and the presence of cryoglobulins was also associated with a worse prognosis.
A difference in survival between patients with myelodysplastic syndrome with systemic manifestations and patients lacking these manifestations has been observed in the presence of systemic vasculitis and/or cryoglobulins.